Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Elizabeth A. Kuczynski"'
Publikováno v:
STAR Protocols, Vol 4, Iss 2, Pp 102144- (2023)
Summary: T cell hematological cancer has a complex interplay with host immune cells, but the ability to experimentally discriminate transferred cancer cells from host cells by flow cytometry is technically challenging. Here, we present a flow cytomet
Externí odkaz:
https://doaj.org/article/919101e6c12b4c2597a090811b44ad36
Publikováno v:
Chinese Journal of Cancer, Vol 35, Iss 1, Pp 1-4 (2016)
Abstract The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies a
Externí odkaz:
https://doaj.org/article/da81875440ca4064a05a28c34e58d4b9
Autor:
Sophie Langdon, Adina Hughes, Molly A. Taylor, Elizabeth A. Kuczynski, Deanna A. Mele, Oona Delpuech, Laura Jarvis, Anna Staniszewska, Sabina Cosulich, Larissa S. Carnevalli, Charles Sinclair
Publikováno v:
OncoImmunology, Vol 7, Iss 8 (2018)
mTOR inhibition can promote or inhibit immune responses in a context dependent manner, but whether this will represent a net benefit or be contraindicated in the context of immunooncology therapies is less understood. Here, we report that the mTORC1/
Externí odkaz:
https://doaj.org/article/299f9df38c444f7c898111e12050fe53
Autor:
Robert S. Kerbel, Paul M. Krzyzanowski, Jessica K. Miller, Yogi Sundaravadanam, Shan Man, Ping Xu, Annabelle Chow, Janna Krueger, Elizabeth A. Kuczynski
A recurring historic finding in cancer drug development is encouraging antitumor effects observed in tumor-bearing mice that fail to translate into the clinic. An intriguing exception to this pattern is immune checkpoint therapy, as the sustained tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baee568ced6be1d2f9250d3b9c574f4a
https://doi.org/10.1158/1535-7163.c.6539352.v1
https://doi.org/10.1158/1535-7163.c.6539352.v1
Autor:
Robert S. Kerbel, Paul M. Krzyzanowski, Jessica K. Miller, Yogi Sundaravadanam, Shan Man, Ping Xu, Annabelle Chow, Janna Krueger, Elizabeth A. Kuczynski
Supplementary Table S1 lists missense mutations in mutagenized EMT-6/P variant cells. Supplementary Table S2 lists driver mutations in mutagenized EMT-6/P variant cells. Supplementary Table S3 lists the results of functional annotation clustering of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::162a56b986da2267586f55fbb33b65ef
https://doi.org/10.1158/1535-7163.22509624
https://doi.org/10.1158/1535-7163.22509624
Autor:
Robert S. Kerbel, Paul M. Krzyzanowski, Jessica K. Miller, Yogi Sundaravadanam, Shan Man, Ping Xu, Annabelle Chow, Janna Krueger, Elizabeth A. Kuczynski
Supplementary Figure S1 shows the gating strategy used to identify tumor-infiltrating immune cells. Supplementary Figure S2 shows in vitro survival and viability of tumor cell variants following mutagen treatment and after their recovery, as well as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6619a1cdd2f93be720ea2c81bfe7c126
https://doi.org/10.1158/1535-7163.22509627
https://doi.org/10.1158/1535-7163.22509627
Autor:
Robert S. Kerbel, Paul M. Krzyzanowski, Jessica K. Miller, Yogi Sundaravadanam, Shan Man, Ping Xu, Annabelle Chow, Janna Krueger, Elizabeth A. Kuczynski
Supplementary materials and methods and legends for Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::473965427a9af0fff6e75ae8f6959256
https://doi.org/10.1158/1535-7163.22509621.v1
https://doi.org/10.1158/1535-7163.22509621.v1
Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC) treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that resistance to sorafenib may have a reversible phenotype. In addition, loss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ee9a3b3f29c8477dc235969e4fb5a4
https://doi.org/10.1158/0008-5472.c.6506811.v1
https://doi.org/10.1158/0008-5472.c.6506811.v1
Supplementary Figure Legend. Legends for Supplementary Figures S1-S5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c07ae8d4fe7bb601d5feb8738fcc58
https://doi.org/10.1158/0008-5472.22405344.v1
https://doi.org/10.1158/0008-5472.22405344.v1
Supplementary Figures S1-S5. Loss of sorafenib resistance in vitro and during transfer of resistant tumor fragments (S1); Sorafenib plasma levels declined in early progressors (S2); Impact of tumor free-mouse treatment on tissue sorafenib metabolite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c3a2b3efcb0118bf3d0d93b6b18dbad
https://doi.org/10.1158/0008-5472.22405341
https://doi.org/10.1158/0008-5472.22405341